Issue 36, 2011

Metal-based antitumour drugs in the post-genomic era: what comes next?

Abstract

In our Dalton Transactions Perspective article entitled, ‘Metal-based antitumour drugs in the post genomic era', (Dalton Trans., 2006, 1929–1933) we discussed metal-based drugs in light of past decades of research. We concluded that the post-genomic era would dictate a change in the direction of the field with knowledge of the genome increasingly allowing protein targets to be identified and not simply assuming that DNA is the only relevant target of metal-based drugs. Since our article was published new insights into the mode of action of metal-based drugs have emerged making some older findings increasingly relevant to current drug design. In this article we discuss these developments in terms of what we believe should be the future direction for the field.

Graphical abstract: Metal-based antitumour drugs in the post-genomic era: what comes next?

Article information

Article type
Perspective
Submitted
28 Mar 2011
Accepted
18 May 2011
First published
04 Jul 2011

Dalton Trans., 2011,40, 9069-9075

Metal-based antitumour drugs in the post-genomic era: what comes next?

G. Sava, A. Bergamo and P. J. Dyson, Dalton Trans., 2011, 40, 9069 DOI: 10.1039/C1DT10522A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements